Yields briefly cracking 5% and then cooling suggests the rate spike may be peaking, and the Fed decision itself is the last big uncertainty this week — Asian markets are trading nervously precisely because everyone is waiting for it. Once the hike lands,

Verdict: A value-rotation entry worth taking — but only after the triggers confirm

The thesis — that yields cooling after briefly topping 5% (per the WSJ report of September 14, 2026) rotates money into real profits and pricing power — fits the fundamentals: KO just expanded gross margin 2.9 points to 63.0% and operating margin 19.4 points to 35.0% in its quarter ended April 3, 2026, and JNJ's latest year shows $94.2B in revenue, a 67.9% gross margin, and $19.7B of free cash flow. The strongest point against is that the basket's weakest link is deteriorating: PG's Q4 (ended June 30, 2026) saw gross margin fall 3.1 points to 46.4% and net margin drop 7.4 points to 11.1%, and June 30, 2026 institutional filings show net insider open-market selling at both JNJ (about -$46.7M) and KO (about -$81.1M). The backtest is positive but modest — 13.5% over 60 months across 19 trades on the JNJ leg with an 11.0% worst drawdown, and a 36.8% win rate, meaning losing trades are the norm and the edge comes from the 2-to-1 stop-to-target geometry. Right now no entry rule is fully triggered: JNJ's RSI leg is met but price must close above its 50-day average at $262.91 (about 1.8% below the $267.79 close) alongside a confirmed MACD cross, and KO needs a close above $89.00. That verdict could flip if JNJ closes above both its 50-day line and the $269.71 resistance with a confirmed MACD cross — the mechanical confirmation the rules require. Until then, the sensible posture is to wait for the trigger rather than pre-position, sizing around an 11% worst-month scenario, not the 2.3% hard stop.

Trade now: three value names, all one daily close away from a trigger

This setup is a **wait**, not a chase. JNJ closed at $267.79 with RSI (14) at 48.1 — already above the 45 requirement — but the first entry condition (the 50-day average, currently $262.91, sitting above price) is not yet met: price needs to trade above roughly $262.91, about $4.88 or 1.8% below the last close. The MACD line also needs a fresh bullish cross of its signal line, which the live reading shows as imminent but not confirmed. KO ($88.47, RSI 48.7) and PG ($147.91, RSI 64.7) mirror the same structure: RSI leg met, price-vs-50-day and MACD-cross legs still pending. No entry rule is fully triggered today. Concretely, "wait" means: hold off until a daily close puts price above its 50-day average alongside a confirmed MACD line-over-signal cross — the stronger variant of each entry also requires a close above the nearest resistance ($269.71 for JNJ, $89.00 for KO, $148.72 for PG). The setup is rules-not-yet-triggered by design, not a lack of evidence: the completed five-year backtest on this exact rule set returned 13.5% across 19 trades on the JNJ leg, with a worst drawdown of 11.0%, and the 12-month window returned 7.3% with a 4.5% drawdown — the historical pattern favors waiting for the trigger rather than pre-positioning. Risk is defined mechanically, not by feel. Positions carry a hard stop at a 2.3% loss on entry price, with the first take-profit at 4.6% — roughly 2-to-1 reward-to-risk per position, and a fixed-risk sizing method that caps each position at 25% of the book. For JNJ, the 2.3% stop from a hypothetical entry near $267.79 is about $261.62; from an entry closer to the $262.91 50-day line it tightens to roughly $256.85. Exit discipline also fires if price closes back below the 50-day average, so the invalidation is two-layered: the percentage stop and the trend line. Two honest caveats on sizing: no robust nearby parameter setup was established (the sensitivity run hit its time budget with zero variants validated), so treat the published thresholds as the strategy, not a tuning suggestion. And SPVU carries no price data at all in this analysis — it cannot be evaluated and should not be traded on this note.

Why the bull case still has support

The macro setup the idea argues — yields cooling after briefly cracking 5% (per the WSJ report of September 14, 2026) and event risk resolving after the Fed decision — is a reasonable on-ramp for a value-factor long, and the completed backtest gives it a realized track record. Over the 60-month daily window, the JNJ leg of the strategy traded 19 times and returned 13.5% with a peak drawdown of 11.0%; the most recent 12-month window added 7.3%. The rule set did not need to be reverse-engineered: the author kept the thesis-consistent trigger framework intact, and the most recent 12-month window added 7.3% with a contained 4.5% drawdown. The fundamentals justify placing these three names in the value bucket. JNJ's latest full year (ended December 28, 2025) shows $94.2B in revenue, up 6.0% year over year, a 67.9% gross margin, $19.7B of free cash flow (top 1% of its 960-stock Health Care peer set), and a 32.9% return on equity. KO's latest year shows $47.9B in revenue with a 61.6% gross margin and a 40.7% return on equity; its most recent quarter (Q1, ended April 3, 2026) expanded gross margin by 2.9 points to 63.0% and operating margin by 19.4 points to 35.0% versus the prior quarter — exactly the real-profits, pricing-power profile the thesis says money rotates toward. PG, despite a soft final quarter, still posted $87.0B in revenue (up 3.3%) and $15.1B of free cash flow for its fiscal year ended June 30, 2026. The income stream is the quieter part of the bull case. All three are serial dividend growers: JNJ paid $5.28 per share over the trailing twelve months with roughly 3.9% annual growth, KO $2.10 with about 4.2% growth, and PG $4.29 with about 4.0% growth. If the idea's rotation into profits over stories plays out, these payouts compound while the position waits. The composition of the basket also matches the thesis more closely than the idea's headline suggests. This is not a speculative-growth long; it is three mega-caps with elite margins and cash generation, so the post-decision value rotation is the thesis working through its intended channel rather than a leverage-on-sentiment bet. One caveat belongs in the bull column too: the backtest's exit fills were approximated on daily bars rather than intrabar data, so the 36.8% win rate and 11.0% drawdown are coarse figures — which means the realized edge may be somewhat better or worse than reported, but the multi-window sample (60, 24, and 12 months) is at least consistently positive in return.

What could break the thesis

The macro trigger is unproven. The idea leans on the WSJ report (September 14, 2026) that the 10-year yield cooled after topping 5% as evidence…

Scores

• Conviction score breakdown: 59
• Thesis support: 64
• Trade readiness: 48
• Risk quality: 55
• Backtest evidence: 62
• Fundamentals trend: 68

Watch items

• JNJ — JNJ price vs 50-day SMA
• KO — KO price vs first resistance
• PG — PG price vs first resistance
• PG — PG net margin (Q4 FY2026, percent)
• JNJ — Institutional net insider open-market flow (JNJ and KO)